StudyReason for exclusion
Abbate I, Cappiello G, Lo Iacono O, et al. Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype with PEG- or STD-IFN plus RBV. J Biol RegulHomeost Agents. Apr-Jun 2003;17(2):162–165.Study design not included
Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis. Apr 2004;43(4):617–623.Study design not included
Anonymous. Hepatitis drug gets approval for coinfection treatment. AIDS Patient Care STDS. May 2005;19(5):351.No original data (e.g., letter, editorial, non- systematic review)
August-Jorg BS, Borovicka J, Dufour JF, et al. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. SwissMed Wkly. 2003;133(33–34):455–460.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Balan V, Schwartz D, Wu GY, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol. Feb 2005;100(2):299–307.Study design not included
Borg BB, Hoofnagle JH. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV Infection.[comment]. N Engl J Med. Sep 15 2005;353(11):1182–1183; author reply 1182–1183.No original data (e.g., letter, editorial, non- systematic review)
Brok J, Gluud L, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews. 2006(3).Intervention not included (e.g., not pegylated interferon, monotherapy only)
Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. Journal of Viral Hepatitis. May 2006;13(5):316–321.Study design not included
Chambers TJ, Fan X, Droll DA, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol. Mar 2005;79(5):3071–3083.Study design not included
Chisholm JA, Williams G, Spence E, et al Retinal toxicity during pegylated alpha-interferon. therapy for chronic hepatitis C: a multifocal electroretinogram investigation. AlimentaryPharmacology & Therapeutics. Mar 15 2005;21(6):723–732.Outcome not included
Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. Journal of Viral Hepatitis. 2003;10(4):298–305Intervention not included (e.g., not pegylated interferon, monotherapy only)
De Kaita K, Wong S, Renner E, Minuk GY. Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials. Can J Gastroenterol. Feb 2006;20(2):87–90.Study design not included
Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. Journal of ViralHepatitis. May 2006;13(5):311–315.Study design not included
Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. Journal of Medical Virology. Apr 2006;78(4):446–451.Study design not included
Di Bisceglie AM, Rustgi VK, Thuluvath P, et al. Pharmacokinetics and pharmacodynamics of Pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology. 2004(Suppl 1):734.Study design not included
Dominguez S, Ghosn J, Valantin M-A, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Aids. May 12 2006;20(8):1157–1161.Population not included (acute hepatitis C infection)
Ferenci P, Bergholz U, Laferl H, al. e. 24 week treatment regimen with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (CPEGUS) in HCV genotype1 or 4 'super responders'. Paper presented at: 41st Annual Meeting of the European Association for the Study of the Liver; April 26–30, 2006; Vienna, Austria.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. AlimentaryPharmacology & Therapeutics. Feb 15 2006;23(4):507–511.Study design not included
Glesby MJ, Bassett R, Alston-Smith B, et al. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. J Infect Dis. Mar 1 2005;191(5):686–693.Study design not included
Heathcote E, Shiffman M, Cooksley W, Dusheiko G, Lee S, Balart L. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl JMed. 2000;343(23):1673–1680.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Henry MJ. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.[comment]. N Engl J Med. Sep 15 2005;353(11):1182–1183; author reply 1182–1183.No original data (e.g., letter, editorial, non- systematic review)
Herrine SK, Brown RS, Jr., Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin a pilot study of efficacy and safety. Dig Dis Sci. Apr: 2005;50(4):719–726.Study design not included
Jacobson IM, Ahmed F, Russo MW, et al. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol.2004;99(9):1700–1705.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. European Journal of Gastroenterology & Hepatology. Sep 2005;17(9):899–904.No original data (e.g., letter, editorial, non- systematic review)
Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clinical Pharmacology & Therapeutics. Jan2005;77(1):90–100.Outcome not included
Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment- refractory chronic hepatitis C. Journal of Hepatology. Aug 2005;43(2):243–249.Study design not included
Lee JS, Hu S, Carlos Lopez-Talavera J. Ribavirin (RBV) dose reduction in patients with HCV genotype 1 infection receiving combination treatment with peginterferon alfa-2A (40KD) (PEGASYS) plus RBV (COPEGUS). Hepatology (Baltimore, Md.).2004;40(4 Suppl 1):335A.No original data (e.g., letter, editorial, non- systematic review)
Lee SS, Bain V, Peltekian K, et al. Peginterferon alfa-2a (40 kDa) plus ribavirin in cirrhotic patients with chronic hepatitis C: results of a Canadian multicenter open-label expanded access program. Journal of Hepatology. 2005;42(Suppl 2):210.No original data (e.g., letter, editorial, non- systematic review)
Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials.2004;25(5):472–492.No original data (e.g., letter, editorial, non- systematic review)
Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. Journal ofMedical Virology. Sep 2005;77(1):66–69.Study design not included
Lindsay K, Trepo C, Heintges T, Shiffman M, Gordon S, Hoefs J. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395–403.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Luo S, Cassidy W, Jeffers L, Reddy KR, Bruno C, Howell CD. Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. Clin GastroenterolHepatol. May 2005;3(5):499–506.Outcome not included
Mangia A, Cimino L, Persico M, et al. Enhanced response to peginterferon-a-2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study. Journal ofHepatology. 2005;42(Suppl 2):200.No original data (e.g., letter, editorial, non- systematic review)
Marino N, Blanc PL, Ble C, Pierotti P, Mazzotta F. Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin. J Biol Regul Homeost Agents. Apr-Jun 2003;17(2):205–206.No original data (e.g., letter, editorial, non- systematic review)
Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. ClinTher. Jul 2004;26(7):991–1025.No original data (e.g., letter, editorial, non- systematic review)
Maynard M, Pradat P, Bailly F, et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). Journal of Hepatology. Mar 2006;44(3):484–490.Study design not included
Mohsen A, Norris S. Chronic hepatitis C. ClinEvid. Dec 2005(14):920–930.No original data (e.g., letter, editorial, non- systematic review)
Myers R, Abdo A, Poynard T. Pegylated interferon alfa for chronic hepatitis C 1. CochraneDatabase of Systematic Reviews. 2006;2:2.No original data (e.g., letter, editorial, non- systematic review)
Myers R, Poynard T. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews.2006;2:2.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Myers R, Regimbeau C, Thevenot T, et al. Interferon for acute hepatitis C [Systematic Review]. Cochrane Database of Systematic Reviews. 2006;2:2.Population not included (acute hepatitis C infection)
Myers R, Regimbeau C, Thevenot T, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews.2006;2:2.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol. Jan 2005;28(1):13–21.Study design not included
Nevens F, Van Vlierberghe H, D'Heygere F, et al. Peginterferon alfa-2a (40 kDa) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy as in naive patients: results from the BERNAR-1 trial. Journal of Hepatology.2005;42(Suppl 2):214.No original data (e.g., letter, editorial, non- systematic review)
Nunez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antiviral Therapy. 2005;10(5):657–662.Outcome not included
Perez R, Jimenez M, Crespo J, et al. Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with chronic hepatitis C. Journal of Viral Hepatitis.2003;10(6):437–445.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis. Mar 2004;11(2):157–165.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Plosker GL, Keating GM. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Drugs.2004;64(24):2823–2843.No original data (e.g., letter, editorial, non- systematic review)
Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol. 2004;99(7):1298–1305.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Poynard T, al. e. EPIC-3 (Evaluation of PEG- Intron in control of hepatitis C cirrhosis). Data on file.Study design not included
Puoti M, Babudieri S, Rezza G, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?[see comment]. Antiviral Therapy. Aug 2004;9(4):627–630.Study design not included
Rasenack J, S. Z, SV. F, et al. Peginterferon alpha-2a (40kD) improves HR-QOL outcomes compared with unmodified interferon alpha-2a: in patients with chronic hepatitis C. Pharmacoeconomics.2003;21(5):341–349.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Reddy K, Wright T, Pockros P, Shiffman M, Everson G, Reindollar R. Efficacy and safety of pegylated (40-kd) interferon < alpha >−2a compared with interferon < alpha >−2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33(2):433–438.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. Aids. Oct 2005;19 Suppl 3:S174–178.Study design not included
Sanchez-Tapias JM, Crespo J, Diago M, Perez R, Romero-Gomez M, Munoz-Sanchez M. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naive patients with chronic hepatitis C virus infection without early virological response at week 4. MethodsFind Exp Clin Pharmacol. Nov 2002;24(9):579–584.No original data (e.g., letter, editorial, non- systematic review)
Shiffman ML. Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. CurrentGastroenterology Reports. Feb 2006;8(1):46–52.No original data (e.g., letter, editorial, non- systematic review)
Simin M, Brok J, Stimac D, Gluud C, Gluud L. Pegylated interferon plus ribavirin versus non-pegylated Interferon plus ribavirin for chronic hepatitis C 1. Cochrane Database of Systematic Reviews. 2006;2:2.No original data (e.g., letter, editorial, non- systematic review)
Soriano V, Maida I, Nunez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antiviral Therapy. Dec 2004;9(6):987–992.Study design not included
Srivastava S, Bertagnolli M, Lewis JH. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naive patients in a university liver clinic. J Natl Med Assoc. Dec2005;97(12):1703–1707.Study design not included
Strinko JM, Di Bisceglie AM, Hoffmann JA. A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role? Issues in mental health nursing.2004;25(7):715–722.Study design not included
Suzuki H, Takagi H, Sohara N, et al. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial. World JGastroenterol. 2006;12(8):1265–1269.Study design not included
Swain M, Lai MY, Shiffman ML, et al. Durability of sustained virological response (SVR) after treatment with peginterferon alfa-2A (40KD) (PEGASYS) alone or in combination with ribavirin(COPEGUS): results of an ongoing long-term follow-up study. Hepatology (Baltimore, Md.). 2004;40(4 Suppl1):400A–401A.No original data (e.g., letter, editorial, non- systematic review)
Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis. Nov 152003;188(10):1498–1507.Outcome not included
Trapero M, Garcia-Buey L, Munoz C, et al. Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev Esp Enferm Dig. Jul 2005;97(7):481–490.Study design not included
Wietzke-Braun P, Meier V, Neubauer-Saile K, Mihm S, Ramadori G. Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients. World JGastroenterol. Oct 21 2005;11(39):6188–6192.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Wilhelmi M, Gubler C, Renner EL, Mullhaupt B. Lymph node enlargement during combination therapy for chronic hepatitis C with pegylated interferon alpha and ribavirin: harmless reaction or harmful disease? Swiss Med Wkly. Jan 21 2006;136(3–4):65–67.Outcome not included
Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. Nov 2002;36(5 Suppl1):S185–194.No original data (e.g., letter, editorial, non- systematic review)
Zeuzem S, Feinman S, Rasenack J, Heathcote E, Lai M, Gane E. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–1672.Intervention not included (e.g., not pegylated interferon, monotherapy only)
Zhang F. Pegylated interferons in the treatment of chronic hepatitis C. Chin Med J. Apr2003;116(4):495–498.No original data (e.g., letter, editorial, non- systematic review)

From: Appendix C. Table of Excluded Studies

Cover of Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection
Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection: Final Report [Internet].
Chou R, Carson S, Chan BKS, et al.
Portland (OR): Oregon Health & Science University; 2007 May.
Copyright © 2007, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.